MORI Yoshiyuki | Second Department of Internal Medicine, Wakayama Medical University

スポンサーリンク

概要

• MORI Yoshiyukiの詳細を見る
• 同名の論文著者
• Second Department of Internal Medicine, Wakayama Medical Universityの論文著者

関連著者

• Ichinose Masao

  Second Department Of Internal Medicine Wakayama Medical University

• Ueda Kazuki

  Second Department of Internal Medicine, Wakayama Medical University

• Tamai Hideyuki

  Second Department Of Internal Medicine Wakayama Medical University

• Inoue Izumi

  Second Department Of Internal Medicine Wakayama Medical University

• Shingaki Naoki

  Second Department Of Internal Medicine Wakayama Medical University

• Iguchi Mikitaka

  Second Department Of Internal Medicine Wakayama Medical College

• Deguchi Hisanobu

  Second Department Of Internal Medicine Wakayama Medical University

• MORIBATA Kosaku

  Second Department of Internal Medicine, Wakayama Medical University

• MORI Yoshiyuki

  Second Department of Internal Medicine, Wakayama Medical University

• MAEKITA Takao

  Second Department of Internal Medicine, Wakayama Medical University

• Oka Masashi

  Second Department Of Internal Medicine Wakayama Medical University

• Enomoto Shotaro

  Second Department Of Internal Medicine Wakayama Medical University

• Yanaoka Kimihiko

  Second Department Of Internal Medicine Wakayama Medical College

• ICHINOSE Masao

  Second Department of Internal Medicine, Wakayama Medical University

• INOUE Izumi

  Second Department of Internal Medicine, Wakayama Medical University

• Kato Jun

  Second Department Of Internal Medicine Faculty Of Medicine Tottori University

• Shiraki Tatsuya

  Second Department Of Internal Medicine Wakayama Medical University

• TUKUDA Hiroshi

  Second Department of Internal Medicine, Wakayama Medical University

• SHIRAI Kiyokazu

  Second Department of Internal Medicine, Wakayama Medical University

もっと見る 閉じる

著作論文

• Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation
• Clinical features and risk factors of extrahepatic seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma
• Low-dose pegylated interferon-alpha-2a monotherapy in elderly and/or cirrhotic patients infected with hepatitis C virus genotype-2 or genotype-1 low level infection

スポンサーリンク